| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/06/2000 | WO2000039279A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | WO2000039278A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 07/06/2000 | WO2000039160A2 Caspase-8 interacting proteins |
| 07/06/2000 | WO2000039158A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | WO2000039143A2 Antiviral nucleoside analogues |
| 07/06/2000 | WO2000039141A1 Inositol-containing hexasaccharides, their synthesis and their uses |
| 07/06/2000 | WO2000039136A2 Human brainiac-5 |
| 07/06/2000 | WO2000039128A1 5ht1 antagonists for antidepressant therapy |
| 07/06/2000 | WO2000039125A1 Piperidines as ccr5 modulators |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038785A2 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | WO2000038747A2 Absorbent article composition and method of use for sequestering skin irritants |
| 07/06/2000 | WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 07/06/2000 | WO2000038729A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038728A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 07/06/2000 | WO2000038727A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038726A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| 07/06/2000 | WO2000038725A1 Combinations for cardiovascular indications |
| 07/06/2000 | WO2000038724A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038723A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| 07/06/2000 | WO2000038722A1 COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
| 07/06/2000 | WO2000038721A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia |
| 07/06/2000 | WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 07/06/2000 | WO2000038716A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 07/06/2000 | WO2000038713A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | WO2000038706A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 07/06/2000 | WO2000038703A1 Agent for treating visual cell function disorder |
| 07/06/2000 | WO2000038699A1 COMPOSITIONS OBTAINED FROM $i(MANGIFERA INDICA L.) |
| 07/06/2000 | WO2000038697A1 Treatment and prevention of hiv and other viral infections |
| 07/06/2000 | WO2000038680A1 Azabicycloalkanes as ccr5 modulators |
| 07/06/2000 | WO2000038679A1 Treatment of retroviral infections with oxyphenbutazone |
| 07/06/2000 | WO2000038678A1 Composition used as medicine and use of same for obtaining a medicine for anaesthesia, in particular analgesic medicine |
| 07/06/2000 | WO2000038676A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 07/06/2000 | WO2000038674A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 07/06/2000 | WO2000038666A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 07/06/2000 | WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038661A2 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 07/06/2000 | WO2000038658A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration |
| 07/06/2000 | WO2000038655A1 Dosage forms comprising porous particles |
| 07/06/2000 | WO2000038652A1 Polyol/oil suspensions for the sustained release of proteins |
| 07/06/2000 | WO2000038626A2 Substrate composition and method of use for sequestration of skin irritants |
| 07/06/2000 | WO2000038625A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 07/06/2000 | WO2000038620A2 A composition useful to treat periodontal disease |
| 07/06/2000 | WO2000038536A2 Inhibitors of the bitter taste response |
| 07/06/2000 | WO2000038515A1 Peptide mimics useful for treating disease |
| 07/06/2000 | WO2000022125A3 6-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 07/06/2000 | WO2000021988A3 Human ankyrin family protein |
| 07/06/2000 | WO2000021512A3 Composition and method for treating allergic diseases |
| 07/06/2000 | WO2000020025A3 Akt compositions for enhancing survival of cells |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020020A3 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 07/06/2000 | WO2000018954A3 Use of pex in the treatment of metabolic bone diseases |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO2000013703A3 Methods of treating hypertension and compositions for use therein |
| 07/06/2000 | WO2000009102A3 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999063115A9 Use of cathepsin s in the diagnosis and treatment of endometriosis |
| 07/06/2000 | WO1999063087A9 G-protein coupled receptor, named 2871 receptor |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999047535A9 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS |
| 07/06/2000 | CA2358687A1 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | CA2358013A1 Compositions obtained from mangifera indica l. |
| 07/06/2000 | CA2357837A1 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356664A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | CA2356661A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | CA2356622A1 Compounds which affect mrna stability and uses therefor |
| 07/06/2000 | CA2356621A1 Assay for identifying compounds which affect stability of mrna |
| 07/06/2000 | CA2356608A1 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides abd uses thereof |
| 07/06/2000 | CA2356607A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356548A1 Human brainiac-5 |
| 07/06/2000 | CA2356547A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | CA2356515A1 Combinations for cardiovascular indications |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356382A1 Agent for treating visual cell function disorder |
| 07/06/2000 | CA2356319A1 Thyroid receptor ligands |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356243A1 Novel guanosine triphosphate (gtp) binding protein-coupled receptor proteins |
| 07/06/2000 | CA2356156A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 07/06/2000 | CA2355097A1 Inositol-containing hexasaccharides, their synthesis and their uses |
| 07/06/2000 | CA2355096A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | CA2354431A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2354053A1 A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| 07/06/2000 | CA2354052A1 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | CA2352423A1 Treatment of retroviral infections with oxyphenbutazone |
| 07/06/2000 | CA2351357A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 07/06/2000 | CA2350685A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration |
| 07/06/2000 | CA2334958A1 Peptide mimics useful for treating disease |
| 07/06/2000 | CA2321672A1 Caspase-8 interacting proteins |
| 07/05/2000 | EP1016418A2 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |